| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/11/2013 | DE102011114864A1 Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat A process for producing a homogeneous powder mixture and process for the preparation of an implant and implant |
| 04/11/2013 | CA2851424A1 Prophylactic and post-acute use of progesterone to better outcomes associated with concussion |
| 04/11/2013 | CA2851398A1 Compositions for the treatment of dry eye |
| 04/11/2013 | CA2851243A1 Compositions for enhancing nail health |
| 04/11/2013 | CA2851177A1 Edible web comprising microorganisms |
| 04/11/2013 | CA2851146A1 Antimicrobial compositions and methods employing same |
| 04/11/2013 | CA2850995A1 Pharmaceutical compositions comprising 40-o-(2-hydroxy) ethyl-rapamycin |
| 04/11/2013 | CA2850919A1 Choline composition |
| 04/11/2013 | CA2850857A1 Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
| 04/11/2013 | CA2850853A1 Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |
| 04/11/2013 | CA2850848A1 Composition for the treatment of fistula |
| 04/11/2013 | CA2849881A1 Pharmaceutical methods and topical compositions containing acitretin |
| 04/11/2013 | CA2849802A1 Process line for the production of freeze-dried particles |
| 04/11/2013 | CA2849799A1 Process line for the production of freeze-dried particles |
| 04/11/2013 | CA2846412A1 Treatment of rhinitis |
| 04/10/2013 | EP2578598A1 Componds derived from normuramyldipeptide |
| 04/10/2013 | EP2578590A2 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
| 04/10/2013 | EP2578237A1 Compositions and methods for enhancing contrast in imaging |
| 04/10/2013 | EP2578234A1 Sugar responsive gel and medicine administering device |
| 04/10/2013 | EP2578215A1 Use of oxaloacetate in the treatment of ischaemia |
| 04/10/2013 | EP2578211A1 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone-based composition and method for the production thereof |
| 04/10/2013 | EP2578209A1 Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| 04/10/2013 | EP2578208A1 DPP-IV inhibitor solid dosage formulations |
| 04/10/2013 | EP2578207A2 Masking apertures enabling automation and solution exchange in sessile droplet lipid bilayers |
| 04/10/2013 | EP2578206A1 Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system |
| 04/10/2013 | EP2578186A2 Drug-delivery endovascular stent and method for treating restenosis |
| 04/10/2013 | EP2578088A1 Edible web comprising microorganisms |
| 04/10/2013 | EP2576813A1 Procedure for biphasic preparation of liposomes and application thereof in manufacturing diagnostic reagents |
| 04/10/2013 | EP2576781A2 Composition and method for inner ear sensory hair cell regeneration and replacement |
| 04/10/2013 | EP2576701A2 Preparation for use in ophthalmology and retinal surgery |
| 04/10/2013 | EP2576591A2 Tablet formulation of ezatiostat |
| 04/10/2013 | EP2575931A2 Drug-delivery accessory for an implantable medical device |
| 04/10/2013 | EP2575896A2 Magnetically responsive membrane structures |
| 04/10/2013 | EP2575892A1 2-iminobiotin formulations and uses thereof |
| 04/10/2013 | EP2575891A1 Formulations preserving bioactivity and methods of their preparation |
| 04/10/2013 | EP2575889A2 Stable pharmaceutical compositions of rapamycin esters |
| 04/10/2013 | EP2575888A2 Nasal immunization |
| 04/10/2013 | EP2575876A1 Multivalent synthetic nanocarrier vaccines |
| 04/10/2013 | EP2575871A1 Oral vaccine comprising an antigen and a toll-like receptor agonist |
| 04/10/2013 | EP2575864A1 Trefoil factors (tff) for the treatment of chronic pulmonary diseases |
| 04/10/2013 | EP2575854A1 Cyclosporin emulsions |
| 04/10/2013 | EP2575845A2 Aqueous formulations for coating microneedle arrays |
| 04/10/2013 | EP2575839A2 Oral formulations for counteracting effects of aging |
| 04/10/2013 | EP2575829A1 Kit for the treatment of onychomycosis by nitric oxide |
| 04/10/2013 | EP2575822A2 Topical pharmaceutical compositions comprising mometasone furoate |
| 04/10/2013 | EP2575821A2 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| 04/10/2013 | EP2575820A1 Controlled release dosage form comprising quetiapine |
| 04/10/2013 | EP2575813A1 Topical etoricoxib formulation |
| 04/10/2013 | EP2575812A2 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid |
| 04/10/2013 | EP2575811A1 Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid |
| 04/10/2013 | EP2575804A1 Methods of treatment of pancreatic cancer |
| 04/10/2013 | EP2575803A1 Methods of treating bladder cancer |
| 04/10/2013 | EP2575798A1 Gastroretentive dosage forms of gaba analogs |
| 04/10/2013 | EP2575796A1 Formulations comprising calcium, vitamin d and vitamin k for osteoporosis |
| 04/10/2013 | EP2575791A2 Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
| 04/10/2013 | EP2575789A1 Diversion-resistant microgranules and microtablets |
| 04/10/2013 | EP2575788A1 Multi phase soft gel capsules, apparatus and method thereof |
| 04/10/2013 | EP2575787A1 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| 04/10/2013 | EP2575786A2 Process for dry powder formulations |
| 04/10/2013 | EP2575785A1 Oral dosage forms of bendamustine and therapeutic use thereof |
| 04/10/2013 | EP2575784A1 Oral dosage forms of bendamustine |
| 04/10/2013 | EP2575783A2 Methods and compositions for oral pharmaceutical therapy |
| 04/10/2013 | EP2575782A2 Effervescent formulations comprising cephalosporin and clavulanic acid |
| 04/10/2013 | EP2575781A1 Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate |
| 04/10/2013 | EP2575780A1 Extended release formulation of pramipexole |
| 04/10/2013 | EP2575779A2 Use of diatomaceous earth in the pharmaceutical industry |
| 04/10/2013 | EP2575778A1 Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| 04/10/2013 | EP2575777A1 Formulation comprising cefpodoxime proxetil and clavulanic acid |
| 04/10/2013 | EP2575776A1 Process for making dry and stable hemostatic compositions |
| 04/10/2013 | EP2575775A1 Process for making dry and stable hemostatic compositions |
| 04/10/2013 | EP2575774A1 Combination therapy methods for treating proliferative diseases |
| 04/10/2013 | EP2575773A2 Synthetic nanocarrier combination vaccines |
| 04/10/2013 | EP2575772A2 Magnetic nanoparticles |
| 04/10/2013 | EP2575771A1 Composition comprising biodegradable polymers for use in a cosmetic composition |
| 04/10/2013 | EP2575770A1 Process for making dry and stable hemostatic compositions |
| 04/10/2013 | EP2575769A2 Stabilized tacrolimus composition |
| 04/10/2013 | EP2575768A1 Aqueous dispersion comprising galactolipids and method for production thereof |
| 04/10/2013 | EP2575767A1 Novel low molecular weight cationic lipids for oligonucleotide delivery |
| 04/10/2013 | EP2575766A1 Novel pharmaceutical compounds |
| 04/10/2013 | EP2575765A2 Oral spray formulations and methods for administration of sildenafil |
| 04/10/2013 | EP2575764A2 Biodegradable lipids for the delivery of active agents |
| 04/10/2013 | EP2575763A2 Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |
| 04/10/2013 | EP2575762A2 Removal of serine proteases by treatment with finely divided silicon dioxide |
| 04/10/2013 | EP2575761A1 Stable multi-dose compositions comprising an antibody and a preservative |
| 04/10/2013 | EP2575760A1 Formulation comprising nicotine and a cation exchange resin |
| 04/10/2013 | EP2575759A1 Formulation comprising nicotine and a cation exchange resin |
| 04/10/2013 | EP2575758A1 Formulation for osteoporosis |
| 04/10/2013 | EP2575757A1 Water soluble formulation comprising a combination of amlodipine and a statin |
| 04/10/2013 | EP2575756A2 Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition |
| 04/10/2013 | EP2575755A2 Orodispersible tablets of erythritol and isomalt |
| 04/10/2013 | EP2575745A1 Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope |
| 04/10/2013 | EP2575743A2 Antiperspirant compositions |
| 04/10/2013 | EP2575736A1 Oral film dosage form having physical-chemical identifier thereon |
| 04/10/2013 | EP2575735A1 Oral film dosage form having indicia thereon |
| 04/10/2013 | EP2575487A1 Oral formulations of bipolar trans carotenoids |
| 04/10/2013 | EP2575458A1 Tocotrienol compositions |
| 04/10/2013 | EP2575457A1 Oral pharmaceutical composition of duloxetine |
| 04/10/2013 | EP2575450A1 Cyclopropene compositions |
| 04/10/2013 | CN202859717U Physical antimicrobial film |
| 04/10/2013 | CN202859700U Traditional Chinese medicine decoction pieces |